ALL has captured market share during the previous slowdown in M&HCV from 23% in 2012 to 28% in 2015. Looks like they are doing the same with LCVs now.
| Monthly Sales of LCV (D+E) | 2020(ALL) | 2019(ALL) | 2020(Tamo) | 2019(Tamo) | 2020(ALL%/ALL+Tamo) | 2019(ALL%/ALL+Tamo) | |
|---|---|---|---|---|---|---|---|
| April | 4280 | 3709 | 13996 | 14620 | 23.41869118 | 20.23569207 | |
| May | 4226 | 3238 | 12695 | 15558 | 24.97488328 | 17.22706959 | |
| June | 4383 | 4534 | 15094 | 16771 | 22.50346563 | 21.28138935 | |
| July | 4205 | 4203 | 10937 | 15624 | 27.77043984 | 21.19836586 | |
| August | 3882 | 4228 | 11082 | 17426 | 25.94226143 | 19.52526092 | |
| Total | 20976 | 19912 | 63804 | 79999 | 24.74168436 | 19.92973747 |
However, LCV contribution is tiny to ALL’s topline. So real impact may not be extra-ordinary to the company’s numbers. LCV might see even higher market share in coming years as they will introduce even more superior products after BS VI transition as planned by management.
Note: TaMo numbers are of SCV segment. TaMo’s numbers of June FY19 & July FY19 are slightly approximated.
Disc: Initiated position in last 90 days. May add more.